Home»Clinical Trials»Clinical Trials Portfolio

Clinical Trials Portfolio

The Upstate Global Health Institute, part of SUNY Upstate Medical University, conducts innovative clinical research aimed at advancing science and medical knowledge to improve the health of our global community. Our highly experienced team includes physician and advanced practitioner clinical researchers, research coordinators, laboratorians and immunologists and research support staff who specialize in operationalizing clinical research plans. Our team has experience with first in human thru phase 3 trials as well as experimental human infection trials. We invite you to contact us to learn how we can support your plans and programs.

To Learn more contact Michelle Klick, Clinical Research Manager at 315-464-5729 or klickm@upstate.edu.

Sort By:

Phase One, Open Label, Homologous Reinfection with Dengue-1-Virus-Live Virus Human Challenge - (DENV-1-LVHC) or Dengue-3-Virus-Live Virus Human Challenge (DENV-3-LVHC) Virus Strains

Study Category

Human Challenge Model

Phase One, Open Label Assessment of a Dengue-3-Virus-Live Virus Human Challenge

Study Category

Human Challenge Model

Phase One, Open Label Expansion of a Dengue-1-Virus-Live Virus Human Challenge – (DENV-1-LVHC) Virus Strain

Study Category

Human Challenge Model

A Phase 1, Double-Blind, Randomized, Placebo-Controlled Study to A Assess the Antiviral Activity and Safety of AT-752 in a Dengue Human Challenge Model (ATEA)

Study Category

Human Challenge Model

A Phase 2a, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of Repeated Oral Doses of JNJ-64281802 Against Dengue Serotype 1 Infection in a Dengue Human Challenge Model in Healthy Adult Participants

Study Category

Human Challenge Model

A Phase One Randomized Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza in Healthy Individuals

Study Category

Vaccine Studies

A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLINDED TRIAL TO EVALUATE THE SAFETY OF A 6-VALENT OspA-BASED LYME DISEASE VACCINE (VLA15) IN HEALTHY CHILDREN 5 THROUGH 17 YEARS OF AGE

Study Category

Vaccine Studies

Controlled Study of Immunogenicity and Safety of the Investigational vYF Candidate Vaccine in Comparison to YF-VAX in Adults (VYF02)

Study Category

Vaccine Studies

A Phase 1/2/3, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Evaluate the Safety, Tolerability, Immunogenicity and Efficacy of SARS-COV2 Vaccine Candidates Against COVID-19 in Healthy Individuals

Study Category

Vaccine Studies

Effect of Antimalarial Drugs on the Immune Response to Rabies Vaccine for Post-Exposure Prophylaxis. A Randomized, Open Label Trial in Healthy US Adults Age 18-60 Years

Study Category

Human Challenge Model

A PHASE 1/2 RANDOMIZED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA IN HEALTHY INDIVIDUALS

Study Category

Vaccine Studies

A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSE(S) OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2

Study Category

Vaccine Studies

Effects of cART Long Term Exposure in HIV Infected Adults

Study Category

HIV Studies

A Multicenter Study to Assess the Clinical Safety and Treatment Strategy of Using PRO 140 SC as Long-Acting Single-Agent Maintenance Therapy for 48 Weeks in Virologically Suppressed Subjects with CCR5-tropic HIV-1 Infection

Study Category

HIV Studies

Personalized Antiplatelet Secondary Stroke Preventing (PASSPoRT)

Study Category

HIV Studies

A Multicenter, Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-Arm Treatment of PRO 140 in Combination With Optimized Background Therapy in Treatment-Experienced HIV-1 Subjects.

Study Category

HIV Studies

Theratechnologies PROMIS HIV Registry Study

Study Category

HIV Studies

Phase 2, Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Budigalimab and/or ABBV-382 in People Living with HIV on Stable Antiretroviral Therapy Undergoing Analytical Treatment Interruption

Study Category

HIV Studies

A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallelgroup, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine administered every two months from a Bictegravir/emtricitabine/tenofovir alafenamide Single Tablet Regimen in HIV-1 Infected Adults who are Virologically Suppressed

Study Category

HIV Studies

A Phase III, randomized, multicenter, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus lamivudine in HIV-1 infected adults who are virologically suppressed

Study Category

HIV Studies

Multiple Patient Program for Lamprene® (clofazimine) for the treatment of Non-Tuberculous Mycobacterial (NTM) Infections

Study Category

Treatment

A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Hospitalized Patients With COVID-19

Study Category

Treatment

Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical COVID-19 Disease

Study Category

Treatment

A Randomized, Double-blind, Placebo-controlled, Clinical Trial of LY3127804 in Patients who are Hospitalized with Pneumonia and Presumed or Confirmed COVID-19

Study Category

Treatment

CIVICs Influenza, SARS-CoV-2, and Other Respiratory Pathogen Screening Protocol for Future Challenge and Vaccination Studies

Study Category

Observational

A Low-Interventional Methodology Study to Obtain Biological Samples From Participants with Suspected Lyme Disease for the Purpose of Developing Clinical Diagnostic Assays

Study Category

Other

Specimen Acquisition for Viral Hepatitis – Analytical Collection Study

Study Category

Observational

Sample Acquisition/Collection for CIM RD002782 Performance Evaluation: Elecsys Anti-HAV II on the cobas e 601 Immunoassay Analyzer

Study Category

Other

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of SAB-185

Study Category

Other

A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Single Dose of Exebacase in Patients Receiving Standard-of-Care Antibiotics for the Treatment of Staphylococcus Aureus Bloodstream Infections (Bacteremia), Including Right-Sided Infective Endocarditis

Study Category

Other

Adaptive Bio Immunesense Lyme PRO-00717 ImmuneSense Lyme Study

Study Category

Observational

Dalbavancin as an Option for Treatment of S. Aureus Bacteremia (DOTS): A Phase 2b, Multicenter, Randomized, Open-Label, Assessor-Blinded Superiority Study to Compare the Efficacy and Safety of Dalbavancin to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated S. Aureus Bacteremia

Study Category

Other

Prospective Cluster Investigation of COVID-19 in Central New York

Study Category

Other

Identification of markers after recent exposure to uninfected Aedes aegypti mosquitoes in human saliva and blood

Study Category

Observational

An open-label multi-center enabling study to evaluate Influenza-Like Illnesses and Severe Influenza Disease in adults aged 65 years and above

Study Category

Observational

LIAISON® LymeDetect® and Tick-Borne Diseases Trial

Study Category

Observational

Phase 1, Randomized, Double-Blind, Placebo-Controlled Trial of Pulse Dosed Ceftriaxone for Post-Treatment Lyme Disease

Study Category

Treatment

A Phase 2, Randomized, Double Blind, Placebo-Controlled Study to Examine the Prophylactic and Treatment Effects of a Single Dose Level of Oral Fenretinide in a Dengue Virus Challenge Model

Study Category

Human Challenge Model

COVID Surveillance Among CNY Healthcare Workers to Improve Understanding of Infection and Disease Risk

Study Category

Observational

AbbVie Inc. / A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Budigalimab and/or ABBV-382 in People Living with HIV on Stable Antiretroviral Therapy Undergoing Analytical Treatment Interruption

Study Category

Treatment